NASDAQ: RCEL
Avita Medical Inc Stock

$3.97-0.15 (-3.64%)
Updated Jun 11, 2026
RCEL Price
$3.97
Fair Value Price
N/A
Market Cap
$122.18M
52 Week Low
$3.22
52 Week High
$7.12
P/E
-2.54x
P/B
-5.27x
P/S
1.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$72.35M
Earnings
-$45.34M
Gross Margin
81.4%
Operating Margin
-55.5%
Profit Margin
-62.7%
Debt to Equity
-3.23
Operating Cash Flow
-$31M
Beta
1.45
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

RCEL Overview

AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine RCEL's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
RCEL
Ranked
#78 of 94

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.68A
$37.61A
$26.35A
View Top Medical Device Stocks

Be the first to know about important RCEL news, forecast changes, insider trades & much more!

RCEL News

Overview

Due Diligence Score

Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RCEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RCEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RCEL due diligence checks available for Premium users.

Valuation

RCEL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.54x
Industry
20.69x
Market
13.95x

RCEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-5.27x
Industry
2.98x

RCEL's financial health

Profit margin

Revenue
$19.3M
Net Income
-$10.6M
Profit Margin
-55.1%
RCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$51.5M
Liabilities
$74.7M
Debt to equity
-3.23
RCEL's short-term liabilities ($66.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RCEL's short-term assets ($31.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.1M
Investing
$2.0M
Financing
$6.1M
RCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RCEL vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
RCELD$122.18M-3.64%-2.54x-5.27x
NNOXD$119.00M+5.56%-1.47x0.85x
SNWVC$126.32M+2.16%7.90x68.73x
MXCTC$117.83M-4.35%-2.97x0.70x
CVRXD$129.76M+1.24%-2.43x4.46x

Avita Medical Stock FAQ

What is Avita Medical's quote symbol?

(NASDAQ: RCEL) Avita Medical trades on the NASDAQ under the ticker symbol RCEL. Avita Medical stock quotes can also be displayed as NASDAQ: RCEL.

If you're new to stock investing, here's how to buy Avita Medical stock.

What is the 52 week high and low for Avita Medical (NASDAQ: RCEL)?

(NASDAQ: RCEL) Avita Medical's 52-week high was $7.12, and its 52-week low was $3.22. It is currently -44.24% from its 52-week high and 23.29% from its 52-week low.

How much is Avita Medical stock worth today?

(NASDAQ: RCEL) Avita Medical currently has 30,776,689 outstanding shares. With Avita Medical stock trading at $3.97 per share, the total value of Avita Medical stock (market capitalization) is $122.18M.

Avita Medical stock was originally listed at a price of $35.60 in Oct 2, 2019. If you had invested in Avita Medical stock at $35.60, your return over the last 6 years would have been -88.85%, for an annualized return of -30.62% (not including any dividends or dividend reinvestments).

How much is Avita Medical's stock price per share?

(NASDAQ: RCEL) Avita Medical stock price per share is $3.97 today (as of Jun 11, 2026).

What is Avita Medical's Market Cap?

(NASDAQ: RCEL) Avita Medical's market cap is $122.18M, as of Jun 13, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avita Medical's market cap is calculated by multiplying RCEL's current stock price of $3.97 by RCEL's total outstanding shares of 30,776,689.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.